Table 3 Univariate analysis of reporting quality scores for included studies

Author numbers

1 ~ 3

67.05

15.51

0.013

4 ~ 6

75.98

10.93

≥ 7

79.46

9.62

Published year

2009 ~ 2015

68.81

12.12

0.045

2016 ~ 2018

73.69

14.15

2019 ~ 2021

78.06

10.78

Language

English

83.51

5.80

< 0.001

Chinese

62.62

9.20

Affiliation of the first author

University

73.96

13.74

0.853

Hospital

74.83

12.55

Region of first author

the east region

74.60

13.98

0.849

the middle region

72.10

14.30

the west region

76.28

7.30

Tumor type

Colorectal cancer

77.59

12.80

0.294

Non-small cell lung cancer

74.42

13.13

Hepatocellular carcinoma

80.73

8.89

Breast cancer

69.26

12.95

Gastric cancer

77.90

14.45

Renal cell carcinoma

69.79

1.47

Myeloid leukemia

73.33

12.36

Other

78.72

3.58

Ovarian Cancer

51.19

1.68

Method of economic evaluation

Cost-utility analysis

78.43

9.27

< 0.001

Cost-effectiveness analysis

55.88

10.04

Cost minimization analysis

45.24

-

Study design

Prospective Study

49.40

3.00

< 0.001

Retrospective Study

59.39

13.14

Modeling Study

78.47

9.12

Source of funding

No funding

78.64

10.81

< 0.001

Government^a

79.58

10.11

Pharmaceutical company

85.16

6.34

Not mentioned

63.72

10.55

Study Perspective

Health insurance system

75.52

10.76

< 0.001

Healthcare system

79.86

9.14

Societal

72.47

12.25

Patient

75.14

12.44

Health Care Provider’s

68.75

-

Not mentioned

50.89

5.32

Time horizon

Not mentioned

61.23

12.68

< 0.001

< 1 year

45.24

-

1–5 year

72.34

8.32

6–10 year

80.38

9.31

> 10 year

82.36

7.08

Total

74.63

12.75